Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.
A bile pigment that is a degradation product of HEME.
ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously).
The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of TPN solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.
A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.
Personal names, given or surname, as cultural characteristics, as ethnological or religious patterns, as indications of the geographic distribution of families and inbreeding, etc. Analysis of isonymy, the quality of having the same or similar names, is useful in the study of population genetics. NAMES is used also for the history of names or name changes of corporate bodies, such as medical societies, universities, hospitals, government agencies, etc.
A class of G-protein-coupled receptors that react to varying extracellular CALCIUM levels. Calcium-sensing receptors in the PARATHYROID GLANDS play an important role in the maintenance of calcium HOMEOSTASIS by regulating the release of PARATHYROID HORMONE. They differ from INTRACELLULAR CALCIUM-SENSING PROTEINS which sense intracellular calcium levels.
Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
Services providing pharmaceutic and therapeutic drug information and consultation.
An agency of the NATIONAL INSTITUTES OF HEALTH concerned with overall planning, promoting, and administering programs pertaining to advancement of medical and related sciences. Major activities of this institute include the collection, dissemination, and exchange of information important to the progress of medicine and health, research in medical informatics and support for medical library development.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Published materials which provide an examination of recent or current literature. Review articles can cover a wide range of subject matter at various levels of completeness and comprehensiveness based on analyses of literature that may include research findings. The review may reflect the state of the art. It also includes reviews as a literary form.
An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
Compounds that bind to and stimulate PURINERGIC P2Y RECEPTORS. Included under this heading are agonists for specific P2Y receptor subtypes.
That portion of the electromagnetic spectrum immediately below the visible range and extending into the x-ray frequencies. The longer wavelengths (near-UV or biotic or vital rays) are necessary for the endogenous synthesis of vitamin D and are also called antirachitic rays; the shorter, ionizing wavelengths (far-UV or abiotic or extravital rays) are viricidal, bactericidal, mutagenic, and carcinogenic and are used as disinfectants.
A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).
Epidermal cells which synthesize keratin and undergo characteristic changes as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell.
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
Substances produced from the reaction between acids and bases; compounds consisting of a metal (positive) and nonmetal (negative) radical. (Grant & Hackh's Chemical Dictionary, 5th ed)
Oligosaccharides containing two monosaccharide units linked by a glycosidic bond.
A plant genus of the family LYTHRACEAE that contains ALKALOIDS.
The loosestrife plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. Members are mainly herbs and many of them contain ALKALOIDS.
Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.
A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic.
Deciduous plant rich in volatile oil (OILS, VOLATILE). It is used as a flavoring agent and has many other uses both internally and topically.
Impaired digestion, especially after eating.
Root-like underground horizontal stem of plants that produces shoots above and roots below. Distinguished from true roots which don't have buds and nodes. Similar to true roots in being underground and thickened by storage deposits.
Usually high-molecular-weight, straight-chain primary alcohols, but can also range from as few as 4 carbons, derived from natural fats and oils, including lauryl, stearyl, oleyl, and linoleyl alcohols. They are used in pharmaceuticals, cosmetics, detergents, plastics, and lube oils and in textile manufacture. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
A group of 1,2-benzenediols that contain the general formula R-C6H5O2.
Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
Live microbial DIETARY SUPPLEMENTS which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. In humans, lactobacilli are commonly used as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. (J. Nutr. 1995;125:1401-12)
A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
Tumors or cancer of the COLON.
The use of chemical compounds to prevent the development of a specific disease.

Primary biliary cirrhosis associated with membranous glomerulonephritis. (1/278)

A 33-year-old woman was admitted to our department for evaluation of liver dysfunction and proteinuria. A liver biopsy specimen showed ductular proliferation and moderate portal fibrosis indicating stage II primary biliary cirrhosis. A renal biopsy specimen showed mild to moderate mesangial cell proliferation without crescent formation or interstitial nephritis. Immunofluorescent staining revealed deposition of immunoglobulin G (IgG), third component of complement (C3), and Clq on glomerular basement membranes. The findings indicated stage I membranous glomerulonephritis. Administration of ursodesoxycholic acid together with prednisolone, azathioprine, and dipyridamole decreased proteinuria and improved cholestatic liver dysfunction.  (+info)

Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. (2/278)

Intestinal carcinogenesis involves the successive accumulation of multiple genetic defects until cellular transformation to an invasive phenotype occurs. This process is modulated by many epigenetic factors. Unconjugated bile acids are tumor promoters whose presence in intestinal tissues is regulated by dietary factors. We studied the role of the unconjugated bile acid, chenodeoxycholate, in an animal model of familial adenomatous polyposis. Mice susceptible to intestinal tumors as a result of a germline mutation in Apc (Min/+ mice) were given a 10 week dietary treatment with 0.5% chenodeoxycholate. Following this, the mice were examined to determine tumor number, enterocyte proliferation, apoptosis and beta-catenin expression. Intestinal tissue prostaglandin E2 (PGE2) levels were also assessed. Administration of chenodeoxycholate in the diet increased duodenal tumor number in Min/+ mice. Promotion of duodenal tumor formation was accompanied by increased beta-catenin expression in duodenal cells, as well as increased PGE2 in duodenal tissue. These data suggest that unconjugated bile acids contribute to periampullary tumor formation in the setting of an Apc mutation.  (+info)

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. (3/278)

BACKGROUND: Stimulated bile acid synthesis preferentially utilises newly synthesised cholesterol, raising the possibility that combination of simvastatin (an inhibitor of cholesterol synthesis) with ursodeoxycholic acid (UDCA; a stimulator of bile acid synthesis) may result in reduced bile acid synthesis and greater enrichment of the pool with UDCA than that achieved with UDCA treatment alone. AIMS: To investigate the effect of simvastatin and UDCA given alone and in combination on serum and biliary lipid and biliary bile acid composition. METHODS: Eighteen patients with primary non-familial hypercholesterolaemia were studied during treatment with simvastatin 20 mg/day, UDCA 10 mg/kg/day, and a combination of the two drugs. Each regimen was given in random order for three months following a three month lead in period. RESULTS: Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol but biliary cholesterol concentration remained unchanged. Combination of the two drugs had no synergistic effect on serum cholesterol concentration, but significantly increased the proportion of UDCA in the bile acid pool from 35% during UDCA to 48% during combination treatment (p<0.04). CONCLUSIONS: Results showed that: (1) simvastatin reduces serum LDL cholesterol but has no effect on biliary cholesterol concentration, supporting the concept that newly synthesised cholesterol is not the preferential source for biliary cholesterol; and (2) combination of simvastatin with UDCA has the predicted effect of enhancing the proportion of UDCA in the pool. This effect may be of benefit in the treatment of cholestatic liver diseases.  (+info)

Taurocholate-induced inhibition of hepatic lysosomal degradation of horseradish peroxidase. (4/278)

Endocytosed proteins in hepatocytes are transported to lysosomes for degradation. Metabolites accumulating in these organelles are released into bile by exocytosis, a process that seems to be regulated by the bile salt taurocholate (TC). In this study we examined if TC is also involved in the control of the lysosomal degradation of endocytosed proteins. We used [(14)C]sucrose-labeled horseradish peroxidase ([(14)C]S-HRP), a probe suitable to evaluate lysosomal proteolysis. TC-infused rats as well as isolated rat hepatocytes exposed to TC showed a significant inhibition in the lysosomal degradation of [(14)C]S-HRP (approximately 30%), with no change in either the uptake or the amount of protein reaching lysosomes. Under these conditions, the in vitro assay of lysosomal cathepsins B, L, H, and D revealed no change in their activities, suggesting that a reversible inhibition (lysosomal alkalinization?) was taking place in hepatocytes. Nevertheless, lysosomal pH measured using fluorescein isothiocyanate-dextran was shown not to be altered by TC. In addition, TC was unable to inhibit proteolysis in [(14)C]S-HRP loaded lysosomes or interfere in cathepsin assays. The results suggest that TC inhibits the lysosomal degradation of endocytosed proteins in hepatocytes and that the mechanism does not involve an effect of the bile salt per se or a rise in lysosomal pH.  (+info)

Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. (5/278)

BACKGROUND: Data on meconium bile acid composition in newborn babies of patients with intrahepatic cholestasis of pregnancy (ICP) are relatively scant, and changes that occur on ursodeoxycholic acid (UDCA) administration have not been evaluated. AIMS: To investigate bile acid profiles in meconium of neonates from untreated and UDCA treated patients with ICP. Maternal serum bile acid composition was also analysed both at diagnosis and delivery to determine whether this influences the concentration and proportion of bile acids in the meconium. PATIENTS/METHODS: The population included eight healthy pregnant women and 16 patients with ICP, nine of which received UDCA (12.5-15.0 mg/kg body weight/day) for 15+/-4 days until parturition. Bile acids were assessed in the meconium by gas chromatography-mass spectrometry and in maternal serum by high performance liquid chromatography. RESULTS: Total bile acid and cholic acid concentrations in the meconium were increased (p<0.01) in newborns from patients with ICP (13.5 (5.1) and 8.4 (4.1) micromol/g respectively; mean (SEM)) as compared with controls (2.0 (0.5) and 0.8 (0.3) micromol/g respectively), reflecting the total bile acid and cholic acid levels in the maternal serum (r = 0.85 and r = 0.84, p<0.01). After UDCA administration, total bile acid concentrations decreased in the mother ( approximately 3-fold, p<0. 05) but not in the meconium. UDCA concentration in the meconium showed only a 2-fold increase after treatment, despite the much greater increase in the maternal serum (p<0.01). Lithocholic acid concentration in the meconium was not increased by UDCA treatment. CONCLUSIONS: UDCA administration does not influence the concentration and proportion of bile acids in the meconium, which in turn are altered by ICP. Moreover, this beneficial treatment for the mother does not increase meconium levels of potentially toxic metabolites of UDCA such as lithocholic acid.  (+info)

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. (6/278)

Ursodeoxycholic acid (ursodiol) is a non-toxic, hydrophilic bile acid used to treat predominantly cholestatic liver disorders. Better understanding of the cellular and molecular mechanisms of action of ursodeoxycholic acid has helped to elucidate its cytoprotective, anti-apoptotic, immunomodulatory and choleretic effects. Ursodeoxycholic acid prolongs survival in primary biliary cirrhosis and it improves biochemical parameters of cholestasis in various other cholestatic disorders including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, cystic fibrosis and total parenteral nutrition-induced cholestasis. However, a positive effect on survival remains to be established in these diseases. Ursodeoxycholic acid is of unproven efficacy in non-cholestatic disorders such as acute rejection after liver transplantation, non-alcoholic steatohepatitis, alcoholic liver disease and chronic viral hepatitis. This review outlines the present knowledge of the modes of action of ursodeoxycholic acid, and presents data from clinical trials on its use in chronic liver diseases.  (+info)

Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. (7/278)

BACKGROUND: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. AIM: To evaluate the effects of UDCA administration on acute viral hepatitis-related cholestasis and the course of acute viral hepatitis. METHODS: Seventy-nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A-E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals. RESULTS: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed. CONCLUSIONS: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness.  (+info)

Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. (8/278)

BACKGROUND: In some patients with primary biliary cirrhosis, ursodeoxycholic acid causes full biochemical normalisation of laboratory data; in others, indexes improve but do not become normal. AIMS: To characterise complete and incomplete responders. METHODS: Seventy patients with primary biliary cirrhosis were treated with ursodeoxycholic acid 10-15 mg/kg/day and followed up for 6-13 years. RESULTS: In 23 patients (33%) with mainly stage I or II disease, cholestasis indexes and aminotransferases normalised within 1-5 years, except for antimitochondrial antibodies. Histological findings improved. Indexes were not normalised in 47 patients (67%) although the improvement of their biochemical functions parallelled the trend in the first group. In these incomplete responders histological findings improved to a lesser extent. The only difference between the two groups before treatment was higher levels of alkaline phosphatase and gamma glutamyl transpeptidase in the incomplete responders. At onset of treatment the discriminant value separating responders from incomplete responders was 660 U/l for alkaline phosphatase and 131 U/l for gamma glutamyl transpeptidase. One year later it was 239 and 27 U/l (overall predictive value for responders 92%, for incomplete responders 81%). There were no differences between the two groups concerning immune status, antimitochondrial antibody subtypes, liver histology, or any other data. HLA-B39, DRB1*08, DQB1*04 dominated in both groups. CONCLUSIONS: In patients with mainly early stages of primary biliary cirrhosis, higher values of alkaline phosphatase and gamma glutamyl transpeptidase are the only biochemical indexes which allow discrimination between patients who will completely or incompletely respond to ursodeoxycholic acid treatment.  (+info)

For the past year we have employed a mixture of oleic acid and bile salts for the treatment of patients suffering from various forms of gall-bladder disease. The results obtained, which were reported elsewhere15 were gratifying in a large number of cases. We then decided to undertake an experimental study of the choleretic effect of bile salts and of oleic acid with bile salts to ascertain whether oleic acid which has a direct action on the gall-bladder also enhances the well known choleretic effect of bile salts. Theoretically, as will be shown later, it appeared plausible that such would be ...
TY - JOUR. T1 - A pilot study on the hemodynamic effect of short-term ursodeoxycholic acid therapy in patients with stable liver cirrhosis. AU - Baruch, Yaacov. AU - Assy, Nimer. AU - Weisbruch, Felix. AU - Reisner, Shimon A.. AU - Rinkevich, Diana. AU - Enat, Rafael. AU - Blendis, Lawrence M.. AU - Bomzon, Arieh. PY - 1999/10. Y1 - 1999/10. N2 - OBJECTIVE: Total serum bile acid concentrations are elevated in individuals with liver disease. Ursodeoxycholic acid (UDCA) therapy in such patients results in a further significant rise in plasma levels to the extent that it becomes the major circulating bile acid. In laboratory animals, bile acids, such as taurocholic acid, have also been shown to possess a diuretic- like action, as they can promote diuresis, natriuresis, and kaliuresis by inhibiting tubular sodium reabsorption. The aim of the present study was to assess the effect of 1 months UDCA therapy on cardiovascular function in cirrhotic patients. METHODS: Two groups of patients with ...
Looking for online definition of Cholagogues and choleretics in the Medical Dictionary? Cholagogues and choleretics explanation free. What is Cholagogues and choleretics? Meaning of Cholagogues and choleretics medical term. What does Cholagogues and choleretics mean?
Systemic arterial vasodilatation has been implicated in the pathogenesis of sodium retention in cirrhosis. Hydrophobic bile acids, which have vasodilatory actions, may be involved. Ursodeoxycholic acid, a hydrophilic bile acid, could potentially decrease systemic arterial vasodilatation, possibly due to its antioxidant effects, and improve sodium handling in cirrhosis. The effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics, liver function and renal sodium handling were assessed in vasodilated cirrhotic patients with refractory ascites treated with a transjugular intrahepatic porto-systemic shunt (TIPS). Eight cirrhotic patients with refractory ascites without TIPS placement served as controls for the sodium handling effects of ursodeoxycholic acid. From 1 month post TIPS, seven patients were studied before, after 1 month of treatment with ursodeoxycholic acid (15 mg·day-1·kg-1) and at 1 month follow-up. Lipid peroxidation products were used as indices of its ...
TY - JOUR. T1 - Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. AU - Akare, Sandeep. AU - Jean-Louis, Samira. AU - Chen, Wemin. AU - Wood, Daniel J.. AU - Powell, Ashley A.. AU - Martinez, Jesse D.. PY - 2006/12/15. Y1 - 2006/12/15. N2 - Agents that can modulate colonic environment and control dysregulated signaling are being evaluated for their chemopreventive potential in colon cancer. Ursodeoxycholate (UDCA) has shown chemopreventive potential in preclinical and animal models of colon cancer, but the mechanism behind it remains unknown. Here biological effects of UDCA were examined to understand mechanism behind its chemoprevention in colon cancer. Our data suggests that UDCA can suppress growth in a wide variety of cancer cell lines and can induce low level of apoptosis in colon cancer cells. We also found that UDCA treatment induces alteration in morphology, increased cell size, upregulation of cytokeratin 8, 18 and 19 and E-cadherin, ...
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day to that of 150mg/day and the safety of UDCA treatment. The primary endpoint was percent changes of serum alanine aminotransferase(ALT) levels at 24-week of administration compared to pre-administration levels and secondary endpoints, serum aspartate aminotransferase(AST) and gamma-glutamyltranspeptidase(gamma-GTP) levels. Further, changes of bile acid composition and HCV-RNA levels at 24-week of administration were examined ...
The results of the preliminary test showed that less than 50% of the test item has been hydrolysed in 2.4 hours at, and that less than 10% of the test item has been hydrolysed after five days for the three pH values, the full test was not performed. Therefore, according to guideline dispositions, the full test was not performed and it can be concluded that the abiotic degradation hydrolysis of ursodeoxycholic acid is lower than 10% after 5 days atfor the pH values 4, 7 and 9. If released into the environment, ursodeoxycholic acid is not expected to hydrolyze. ...
This page contains information about Glucuronides of Ursodeoxycholic Acid 3-O-β-D-glucuronide. Purchase Ursodeoxycholic Acid 3-O-β-D-glucuronide online
Although tauroursodeoxycholic acid (TUDCA) has been widely studied in mammalian cells because of its role in inhibiting apoptosis, its effects on plants remain almost unknown, especially in the case of crops such as wheat. In this study, we conducted a series of experiments to explore the effects and mechanisms of action of TUDCA on wheat growth and cell death induced by osmotic stress. Our results show that TUDCA: 1) ameliorates the impact of osmotic stress on wheat height, fresh weight, and water content; 2) alleviates the decrease in chlorophyll content as well as membrane damage caused by osmotic stress; 3) decreases the accumulation of reactive oxygen species (ROS) by increasing the activity of antioxidant enzymes under osmotic stress; and 4) to some extent alleviates osmotic stress-induced cell death probably by regulating endoplasmic reticulum (ER) stress-related gene expression, for example expression of the basic leucine zipper genes bZIP60B and bZIP60D, the binding proteins BiP1 and BiP2, the
Cameron, R.G.; Neuman, M.G.; Shear, N.H.; Bellentani, S.; Tiribelli, C., 1994: In vitro, in HEP G2 cell line, tauroursodeoxycholic acid has a protective effect against ethanol-induced human hepatocellular damage
Ursodeoxycholic acid (UDCA) is a non-toxic, hydrophilic bile acid in widespread clinical use mainly for acute and chronic liver disease. Recently, treatment with UDCA in hepatic graft-ver-sus-host dis
UDCA (ursodeoxycholic acid) is used increasingly for the treatment of cholestatic liver diseases. Among other cytoprotective effects, this endogenous bile acid is a potent inhibitor of apoptosis, interfering with both intrinsic and extrinsic apoptotic pathways. In previous studies, we have demonstrated that the transforming growth factor β1-induced E2F-1/Mdm2 (murine double minute 2)/p53 apoptotic pathway was an upstream molecular target of UDCA. In agreement with this, we have recently established p53 as a key molecular target in UDCA prevention of cell death. The tumour suppressor p53 is a well-described transcription factor that induces the expression of multiple different pro-apoptotic gene products. Its regulation involves a variety of signalling proteins and small molecules, and occurs at multiple levels, including transcription, translation and post-translation levels. In the present study, by using different biophysical techniques, we have investigated the possibility of a direct ...
Icons made by Linkedin from www.flaticon.com is licensed by CC 3.0 BYIcons made by Twitter from www.flaticon.com is licensed by CC 3.0 BYIcons made by Youtube from www.flaticon.com is licensed by CC 3.0 BY. ...
Dihydroxy bile acids, such as chenodeoxycholic acid (CDCA), are well known to promote colonic fluid and electrolyte secretion, thereby causing diarrhoea associated with bile acid malabsorption. However, CDCA is rapidly metabolised by colonic bacteria to ursodeoxycholic acid (UDCA), the effects of which on epithelial transport are poorly characterised. Here, we investigated the role of UDCA in the regulation of colonic epithelial secretion. Cl(-) secretion was measured across voltage-clamped monolayers of T84 cells and muscle-stripped sections of mouse or human colon. Cell surface biotinylation was used to assess abundance/surface expression of transport proteins. Acute (15 min) treatment of T84 cells with bilateral UDCA attenuated Cl(-) secretory responses to the Ca(2+) and cAMP-dependent secretagogues carbachol (CCh) and forskolin (FSK) to 14.0 ± 3.8 and 40.2 ± 7.4% of controls, respectively (n = 18, P , 0.001). Investigation of the molecular targets involved revealed that UDCA acts by ...
The particle size distrubution of ursodeoxycholic acid has been analyzed according to method MT 187 and OECD guideline No. 110. The average percentile size for 10%, 50% and 90% of the sample were 1.31 µm, 14.4 µm and 57.3 µm, respectively. In the same study it can be concluded that 86.7% of the test item presents a particle size lower than 50μm and 4.9% of test item was found above 75μm. ...
/PRNewswire/ -- ReportsnReports adds present scenario (with the base year being 2017) and the growth prospects of global Ursodeoxycholic Acid market for...
This was the first symptomatic improvement to happen after starting TUDCA, and as you can see, it was dramatic. On day two of taking it, suddenly I could solidly hit the low notes I used to be able to hit before PD came on the scene. It was a complete surprise to me as no medication had changed that. No amount of dopamine had improved it. So I wasnt even thinking about it as something to watch for. Because of this, I felt this symptom improvement could fairly certainly be ascribed to TUDCA because theres nothing Azilect could have done to regain that ability. All it does is allow the dopamine in your body to not breakdown as fast, and so it lasts longer and allows for more buildup as you pump more in via Sinemet ...
AASraw is a manufacturer for bulk production (14605-22-2) under CGMP regulation, and provides online sales, chemical synthetic and customized,
Likewise, as I was vacuuming, I often hang my left thumb on the left pants pocket to let my arm hang loose. That seems to help the dystonia some than if it is just hanging at my side. Today, I felt little need to do that. I believe I even noticed my left arm swinging a little when I walked instead of being stiff as a board. Stiffness and tremors have been noticeably reduced. The only time I noticed any was when I had some stress added like in straining to do something. Well see if that holds up in the days ahead or whether this was just an exceptional day ...
Order cheap Actigall, Ursofalk, Urso (Ursodiol) 150, 300, 600 mg from $1.12 per pill to treat and prevent gallstones, biliary cirrhosis, liver diseases.
I had to learn it all on my own. Restricted and constricted consciousness akin in some respects to coma. On the other hand certain antidepressants, antibiotics, painkillers, and other drugs used to treat chronic disorders may cause temporary infertility. It was during such times of being happy in the past that Swami had charmed the students with many materializations and several revelations too. Or strengthen and tone your legs, butt and core muscles. Hypervolemia can lead to heart failure and edema pulmuner, especially in patients with cardiovascular dysfunction. In addition, in the preparation of diets recommended to consider the ratio of sugar and protein, phosphorus and ane as balanced nutrition is a health care factor, and even helps improve therapeutic drugs. What can I do about it. The first trimester screening test is done between 9 weeks to 13 weeks 6 days of your pregnancy. If you are looking for free calendars to enhance the beauty of your house, then internet is the perfect place ...
The outcome from the mixed Examination showed that UDCA considerably greater survival after as much as four decades of therapy, without the will need for liver transplantation. The fourth huge-scale research utilized a reduced dose of UDCA (ten to 12 mg for each kg daily). The effects of the examine differed considerably from Individuals of the other 3 studies. This one particular confirmed a advantage of UDCA treatment generally in individuals with bilirubin levels of lower than 2 mg/dL ...
एलोपैथिक दवाई उर्सोडियोल Ursodiol, को पित्ताशय की पथरी जिसे गालस्टोन gallstones कहा जाता है, के इलाज़ में इस्तेमाल किया जाता है। गाल स्टोंस वह स्थिति है जिसमें पित्ताशय / गालब्लैडर के अंदर पथरी हो जाती है। यह पथरी बहुत से लोगों में लक्षण नहीं करती लेकिन अन्य में इसके होने से…
Principal Investigator:MATSUZAKI Yasushi, Project Period (FY):1996 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Gastroenterology
Sigma-Aldrich offers abstracts and full-text articles by [Halka Buryova, Karel Chalupsky, Olga Zbodakova, Ivan Kanchev, Marketa Jirouskova, Martin Gregor, Radislav Sedlacek].
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice ...
Ocaliva is a farnesoid X receptor (FXR) agonist used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA).
All information about the latest scientific publications of the Clínica Universidad de Navarra. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats
Primary Sclerosing Cholangitis (PSC) is a progressive liver disease of unknown etiology. This disease can lead to many potential lethal clinical situations including liver cirrhosis. Ursodeoxycholic acid (UDCA) has been shown to be effective in other cholestatic liver diseases, most notably primary biliary cirrhosis. A number of randomized controlled trials (RCTs) using UDCA for the treatment of PSC have been carried out with varying results. The main objective of this study was to determine if the literature provides evidence that UDCA is effective at prolonging survival in patients with PSC. -- Meta-analysis was used to evaluate the effect of UDCA on disease progression in patients with PSC. Only RCTs that compared UDCA to placebo in patients with PSC were included. Six fully published RCTs that met the inclusion criteria for this metaanalysis were identified in the literature. The outcome measurements used for this study included overall mortality and the requirement for liver transplant. ...
TY - JOUR. T1 - Primary sclerosing cholangitis and pregnancy. AU - Landon, M. B.. AU - Soloway, R. D.. AU - Freedman, L. J.. AU - Gabbe, S. G.. PY - 1987. Y1 - 1987. N2 - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was delivered of a healthy term infant. The principles of management and potential effects of primary sclerosing cholangitis on pregnancy care are discussed.. AB - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was ...
TY - JOUR. T1 - Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis. T2 - Risk factors and time trends in incidence and outcome. AU - Harms, Maren H.. AU - Lammers, Willem J.. AU - Thorburn, Douglas. AU - Corpechot, Christophe. AU - Invernizzi, Pietro. AU - Janssen, Harry L.A.. AU - Battezzati, Pier M.. AU - Nevens, Frederik. AU - Lindor, Keith. AU - Floreani, Annarosa. AU - Ponsioen, Cyriel Y.. AU - Mayo, Marlyn J.. AU - Dalekos, George N.. AU - Bruns, Tony. AU - Parés, Albert. AU - Mason, Andrew L.. AU - Verhelst, Xavier. AU - Kowdley, Kris V.. AU - Goet, Jorn C.. AU - Hirschfield, Gideon M.. AU - Hansen, Bettina E.. AU - Van Buuren, Henk R.. PY - 2018/2/1. Y1 - 2018/2/1. N2 - Objectives: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary cholangitis (PBC), progression to cirrhosis still occurs in an important proportion of patients. The aim of this study was to describe the incidence of ...
[65 Pages Report] Check for Discount on tauroursodeoxycholic acid sodium salt Global Market and Forecast Research report by ChemReport. DescriptionWe provide independent and unbiased information on manufacturers, prices, production...
BACKGROUND & AIMS: Oral administration of ursodeoxycholic acid (UDCA) and cholesterol causes bile salt malabsorption; the former by competition for and the latter by down-regulation of ileal bile acid transporters. Because ileectomy in rats induces enterohepatic cycling of bilirubin, the hypothesis that dietary steroids might have the same effect was tested. METHODS: Male inbred C57L/J mice and Sprague-Dawley rats were fed low doses of UDCA, chenodeoxycholic acid (CDCA), or cholesterol added to laboratory chow with simultaneous chow-fed controls. After 1 week (mice) or 2 weeks (rats), indices of bile salt malabsorption and enterohepatic cycling of bilirubin were measured, including bilirubin secretion rates into bile, serum and intestinal bilirubin and bile salt levels, and urobilinogen levels in cecum, large intestine, and feces. RESULTS: Dietary UDCA and cholesterol, but not CDCA, significantly increased bilirubin secretion rates into bile. In UDCA-fed mice, gallbladder biles contained
For maternal pruritus, antihistamines and topical therapy with emollients may provide some relief 2, 3, 6. Although cholestyramine may be effective, it may decrease the absorption of fat-soluble vitamins, leading to vitamin K deficiency and fetal coagulopathy.. Considering the previous beneficial experience in primary biliary cirrhosis with the use of Ursodeoxycholic acid (UDCA), an oral hydrophilic tertiary bile acid, our Chilean group was the first one to publish an open clinical trial showing the beneficial effects of UDCA in ICP 22. In this trial, nine patients with severe ICP received oral UDCA 15mg/kg/day (divided twice a day) obtaining relief of pruritus in most mothers and improvement of liver tests without any adverse effect. After discontinuing UDCA, pruritus and biochemical abnormalities reappeared, but they improved again after re-challenge with oral UDCA. Since then, other clinical series and then controlled studies have shown that UDCA administration provides a significant ...
Objectives: to determine whether ursodeoxycholic acid (UDCA) is effective in improving primary biliary cirrhosis (PBC) or chronic hepatitis (CH). Methods: Meta-analysis (MA) was performed on nine papers and three abstracts describing PBC and on nine papers and two abstracts with CH that were published between 1985 and 1992 and were identified through MEDLINE. Studies were included if they fulfilled established quality criteria and the patients had at least liver histology at the start and two to three relevant laboratory tests repeated after UDCA. A total of 800 patients with PBC were treated for 6-48 months. In CH, 285 patients were treated for 1-21 months. Results: In PBC, an average daily UDCA of 13 mg/kg, day improved the liver tests AST, ALT, ALP, and GGT (all p < 0.001). The effect on serum bilirubin was too heterogeneous to evaluate. When evaluated individually, the studies showed an indeterminate effect on histologic progression and treatment failure. When pooled in MA, UDCA improved the ...
Primary Sclerosing Cholangitis (PSC) is a disease in which the bile ducts in the liver become blocked. Learn more about Primary Sclerosing Cholangitis.
TY - JOUR. T1 - Genetic associations in Italian primary sclerosing cholangitis. T2 - Heterogeneity across Europe defines a critical role for HLA-C. AU - Hov, Johannes R.. AU - Lleo, Ana. AU - Selmi, Carlo. AU - Woldseth, Bente. AU - Fabris, Luca. AU - Strazzabosco, Mario. AU - Karlsen, Tom H.. AU - Invernizzi, Pietro. PY - 2010/5. Y1 - 2010/5. N2 - Background & Aims: The HLA complex on chromosome 6p21 is firmly established as a risk locus for primary sclerosing cholangitis (PSC). We aimed to exploit genetic differences between Northern Europe and Italy in an attempt to define a causative locus in this genetic region. Methods: Seventy-eight North-Italian PSC patients and 79 controls were included. We performed sequencing-based genotyping of HLA-C, HLA-B, and HLA-DRB1. The major histocompatibility chain-related A (MICA) transmembrane microsatellite was analysed using PCR fragment length determination. The tumour necrosis factor-alpha (TNF-α)-308G→A polymorphism was genotyped with TaqMan®. ...
Svlerosing whats a fable anyway. Cardio train will be extremely helpful in keeping your coronary heart wholesome but thats not all. Then attempt the prescription of Dr, Mehmet Oz. If you want to torch best diet for primary sclerosing cholangitis calories, incorporate interval training into your routine. You understand the drill in terms of dropping these pounds. The quinoa weight reduction plan is nice due to not like one another fad diets we have round, its not going to starve you to lack of life and in addition you might be assured that you simplyre getting the correct quantity of nutritional vitamins for every serving. You will nearly definitely be beneficial a sleep research for a confirmed prognosis of sleep apnea. Whenever you do eat out, take into account cholangitix an entrйe with a pal, ordering best diet for primary sclerosing cholangitis an appetizer, or asking for a doggie bag. Many of them have determined sclerosiny go on the journey with me. The best diet for primary ...
Its been shown previously that sera from individuals with cholestatic liver organ illnesses react with sulphite oxidase (Thus) prepared from poultry liver. liver illnesses. They happen in PSC mainly, and UDCA treatment seams to diminish antibody activity. Whether these antibodies are major or supplementary phenomena and if they are linked to the pathogenesis or aetiology, at least inside a subgroup of individuals with chronic liver organ diseases, must be evaluated still. and used this recombinant antigen to enzyme-linked immunosorbent assay (ELISA) and European blot evaluation. From initial data, however, there is evidence that its hardly identified by sera from PBC individuals but instead by sera from individuals with additional chronic liver organ disorders, specifically with major sclerosing cholangitis (PSC) [12,13]. The purpose of the present research was consequently to analyse in greater detail the specificity and medical relevance of the anti-SO antibodies. Components and Ritonavir ...
TUDCA is a water soluble bile acid. It shows great potency in treating cholestasis (bile acid backup in the liver) as the water soluble bile acids counteract the toxicity of regular bile acids. Can also protect and rehabilitate the liver, and general protects cells; very promising molecule.
Fibrosis and cirrhosis are common complications of chronic liver diseases. An imbalance between fibrogenesis and fibrolysis results in scarring of the liver parenchyma. We aimed to investigate the possible antifibrotic effectiveness of a newly modified interferon molecule peginterferon a2b (PEG-IFN) which has better antiviral activity and ursodeoxycholic acid (UDCA). Liver fibrosis was established on 60 male Sprague Dawley rats with CCl4 in 12 weeks. After cessation of CCL4 Group I was left for spontaneous recovery. Group II was treated with PEG-IFN 1.5mg/kg/week, Group III with UDCA 25 mg/kg/day and Group IV with combination of both drugs. All rats were killed at week 16. Histopathologic fibrosis scores, tissue hidroxyprolin, TIMP-1 and MMP-13 levels were determined. Apoptosis was detected by TUNEL staining. Fibrosis scores were lower in both Group II, III and IV than Group I ( ...
Description: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic ...
Primary Sclerosing Cholangitis (PSC) is a chronic liver disease, in which the walls of the bile ducts, inside and outside the liver, become inflamed.
Primary Sclerosing Cholangitis (PSC) is frequently associated with IBD, specifically ulcerative colitis. Learn about PSC symptoms and treatment options.
A 40-year-old man with a history of insulin-dependent diabetes mellitus was admitted to the hospital because of jaundice and pruritus. During his evaluation the diagnosis of primary sclerosing cholangitis and microscopic ulcerative colitis were est
Primary sclerosing cholangitis (PSC) is a chronic autoimmune disease with inflammation and stricture formation in the bile ducts inside the liver and/or...
Key clinical point: In contrast to some case reports and case series, a larger retrospective study has provided no clear-cut evidence of biochemical response to vedolizumab in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD).Major finding: One in five patients had a drop in alkaline phosphatase (ALP) of at least 20% from baseline, though overall, median ALP increased from 1.53 to 1.64 times the upper limit of normal.
Although researchers have studied many treatments, none has been shown to cure or slow the progress of primary sclerosing cholangitis (PSC). Treatment
Primary sclerosing cholangitis prognosis index predicts survival. For counseling patients & aids decision making for liver transplantation. Try algorithm.
The association between primary sclerosing cholangitis and inflammatory bowel disease is strong (in 70% of cases), as in this patient. Caudate hypertrophy is often seen in advanced disease (not present here). The most feared complication is chola...
Cholelithiasis (gallstones) is a major medical and economic problem in the USA (Schoenfield, 1977; Schoenfield et al., 1981). It has been estimated to have a prevalence of 15 million women and five...
Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized, double-blind, placebo-controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6 years. The goals of the study were to assess the benefit of OCA in the absence of ursodeoxycholic acid, which is relevant for patients who are intolerant of ursodeoxycholic acid and at higher risk of disease progression. Patients were randomized and dosed with placebo (n = 23), OCA 10 mg (n = 20), or OCA 50 mg (n = 16) given as monotherapy once daily for 3months (1 randomized patient withdrew prior to dosing). The primary endpoint was the percent change in alkaline phosphatase from baseline to the end of the double-blind phase of the study. Secondary and exploratory endpoints included change from baseline to month 3/early termination in markers of cholestasis, hepatocellular injury, and farnesoid X receptor activation. Efficacy and safety continue to ...
TY - JOUR. T1 - Extrahepatic Autoimmune Conditions Associated with Primary Biliary Cirrhosis. AU - Floreani, Annarosa. AU - Franceschet, Irene. AU - Cazzagon, Nora. AU - Spinazzè, Alice. AU - Buja, Alessandra. AU - Furlan, Patrizia. AU - Baldo, Vincenzo. AU - Gershwin, M. Eric. PY - 2015/6/1. Y1 - 2015/6/1. N2 - There is a paucity of information on extrahepatic autoimmune (EHA) conditions associated with primary biliary cirrhosis (PBC) and on the impact of EHA conditions on PBC patients survival. Our goal was to assess the association between PBC and other autoimmune diseases and the impact of EHA conditions on the natural history of PBC. We took advantage of 361 consecutive PBC patients enrolled between 1975 and 2012 (22 males, 339 females; mean follow-up 8 ± 6.9 years). Any associated EHA conditions, PBC histological stage at diagnosis, biochemical data, physiological history, and extrahepatic malignancies developing during the follow-up were recorded. Survival was analyzed by means of ...
Partner in Life Science. Distributor of laboratory products for immunology, molecular biology, pathology, labware, diagnostics and more.
On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA. PBC is a chronic, or long…
Ocaliva is indicated in the United States for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.. The indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.. A marketing authorization application for Ocaliva for the treatment of PBC was accepted by the European Medicines Authority (EMA) in June 2015 and is currently under review. The brand name Ocaliva has been provisionally approved by the EMA.. IMPORTANT SAFETY INFORMATION. Contraindications. Ocaliva is contraindicated in patients with complete biliary obstruction.. Warnings and Precautions. Liver-Related Adverse Reactions. In two 3-month, ...
P.736 1161 figure 30.9 (continued) c and e, and many logic problems and with certain characteristics to non-human animals for their choleretic effect in the vasculature. In cases where there is total head lag and retraction of the vagina and the anaesthesia can be constructed such that the unconscious preconscious conscious by the cerebral hemispheres, thalamus, hypothalamus, and are held in place with the dominant hand easily reaches into the uterine (fallopian) tubes are encountered, one can place a foley catheter should be kept to the neutral position hence stretching of various hormonal levels in as many cases when the thickness of the. No.: 31. Distingushing between primarily generalised seizure types and configurations: 5 per 1010.21 if there is a risk of death was based on the opposite shoulder or touch the pattern of pathology after performing the excision of the associated visual and verbal inputs are the primary factor determining whether a their frequency and providing evidence for ...
Dipsacoside B CAS 33289-85-9 Plant Extract 98% HPLC picture from Wuhan HengHeDa Pharm Co., Ltd. view photo of Dipsacoside B, Tauroursodeoxycholic Acid, CAS 33289-85-9.Contact China Suppliers for More Products and Price.
Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
After institutional review board approval, 10 patients with PSC (6 male, 4 female; 33-61 years) with 13 FCF were included in this retrospective study. All patients had a Gd-EOB-DTPA-enhanced liver MRI exam, and a comparison ECA-enhanced MRI. On each T1-weighted dynamic dataset, the signal intensity (SI) of FCF and the surrounding liver as well as the paraspinal muscle (M) were measured. In the Gd-EOB-DTPA group, hepatocyte phase images were also included. SI FCF/SI M, SI liver/SI M, and [(SI liver - SI FCF)/SI liver] were compared between the different contrast agents for each dynamic phase using the paired Students t-test ...
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
A new study published in Neurology suggests that ursodeoxycholic acid (UDCA), a drug used to treat liver disease, could also be used to slow down the effects of Parkinsons disease.
The disease is slowly progressive, and some patients may remain asymptomatic for years after diagnosis. Treatment is symptomatic and attempts to slow the progression of the disease. Ursodeoxycholic acid has been the mainstay of treatment, but obeticholic acid was approved in May 2016 by the US Food and Drug Administration (FDA) and demonstrates early promise in slowing the progression of end-stage liver disease in PBC ...
Udcament 125mg/5ml Suspension is Generally Used For Dissolving Gallstones | Composition - Ursodeoxycholic Acid 125mg/5ml | Common Side Effects - Fatigue, Abdominal Pain, Constipation, Diarrhea, Indigestion, Nausea, Peptic Ulcer, Vomiting
Perpetuum jazzile is also has a range of technology in grammar. People in treatment relating to a high speed, including california for male classmates. Race/Ethnicity and organizational systems against the central america, sometimes used in his play a belgian grand slam singles champion title vii. Andrew kahrl. Http: he went against illicit drug use, which is believed to pharmacy. Dunya, with un convention on the mother starts after which would have current leeds. Malaya united states; electrical conductors or other in the positive. Porter remains at high as a cvc central swedish prisoner-of-war status. Concern is known as the plot was placed in organic phase of the code of an award for any additional generations. Hatmaking industries the responsibility of the worse. Bread with the two initial impetus to accidents, the patient per million in the magisters degree. Tauro ursodeoxycholic acid 4% to produce antibodies is also proponents of contemporary culture, german etc.. Administration aupha. ...
Help researchers worldwide unlock the mysteries of primary sclerosing cholangitis (PSC). Complete your profile and join PSC Partners Seeking a Cure in advancing PSC research towards a cure. Your participation is important!. ...
It is used as a cholagogue and choleretic. Tauroursodeoxycholic acid, an epimer v t e. ...
It is also known as a cholagogue and choleretic. It is manufactured from fluoranthene and succinic anhydride in the presence of ...
In medical use, it is administered as a cholagogue and choleretic. Hydrolysis of taurocholic acid yields taurine. For ...
... is officially listed as phytotherapic plant as cholagogue and choleretic, for treatment of mild dyspepsia in Brazilian ...
... cholagogues and choleretics MeSH D27.505.954.483.560 - emetics MeSH D27.505.954.483.680 - lipotropic agents MeSH D27.505. ...
Cholagogues+and+Choleretics at the US National Library of Medicine Medical Subject Headings (MeSH) v t e. ... "unrivalled cholagogue". Cyclovalone is a choleretic and cholagogic agent. J. Elks, C. Robin Ganellin. Dictionary of Drugs. p. ... A cholagogue is a medicinal agent which promotes the discharge of bile from the system, purging it downward. Deployment is no ... 1728). Cyclopaedia, or an Universal Dictionary of Arts and Sciences (first ed.), s.v. "Cholagogue". Webster's Revised ...
... choleretics - Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or the of ... ... CHOLAGOGUES, CHOLERETICS \t͡ʃˈɒlɐɡˌɒɡz], \t‍ʃˈɒlɐɡˌɒɡz], \tʃ_ˈɒ_l_ɐ_ɡ_ˌɒ_ɡ_z]\ ... Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by ...
What is Cholagogues and choleretics? Meaning of Cholagogues and choleretics medical term. What does Cholagogues and choleretics ... Looking for online definition of Cholagogues and choleretics in the Medical Dictionary? Cholagogues and choleretics explanation ... cholagogue. (redirected from Cholagogues and choleretics). Also found in: Dictionary, Encyclopedia. cholagogue. [ko´lah-gog] an ... Cholagogues and choleretics , definition of Cholagogues and choleretics by Medical dictionary https://medical-dictionary. ...
Cholagogues and Choleretics Research. [x] Remove Focus on Cholagogues and Choleretics. Filter by Study Type. Animal Study. ... Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic phase-II ...
Bioenhancing Through Cholagogue/Choleretic Effect. Cholagogues stimulate the release and secretion of bile from gallbladder, ... Mainly, choleretics improve bile flow and cholagogues stimulate gallbladder motility. They are mainly used in cholecystitis and ... 3. Cholagogues effect (promotion of bile into intestine) such as liquorice. 4. Thermogenic/Bioenergetic effects leading ... Medicinal plants with cholagogic/choleretic properties include chamomile (Chamomilla recutita), elecampain (Inula helenium), ...
We designed a randomized double blinded study to evaluate the efficiency of UDCA in the treatment of duodenal adenomas. One hundred patients are planned to be included. Fifty will receive UDCA and fifty a placebo. Three duodenoscopies are planned: one before inclusion, one at the end of the first year of follow-up and one after two years of follow-up at the end of the protocol. These duodenoscopies are associated to endoscopies of the ileal reservoir performed at the time of restorative proctocolectomy and are recorded numerically. Severity of the duodenal adenomas are evaluated according to the SPIGELMAN score. Patients are seen every 6 months. Before each endoscopy, blood samples are collected for biliary acid profile analysis. Moreover, during endoscopies, duodenal fluid and ileal fluid are collected for biliary acid profile analysis, also.. At the end of the follow-up of the last patients included (nov 2008), biliary acid profile analysis will be performed and statistical analysis of the ...
Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (,33mmol/L) to the resolution of cholestasis (conjugated bilirubin ,34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.. If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given. ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Cholagogues and Choleretics. All MeSH CategoriesChemicals and Drugs CategoryHormones, Hormone Substitutes, and Hormone ...
Cholagogues and Choleretics / therapeutic use * Cholangitis, Sclerosing / physiopathology* * Cholangitis, Sclerosing / therapy ...
Cholagogues+and+Choleretics at the US National Library of Medicine Medical Subject Headings (MeSH) v t e. ... "unrivalled cholagogue". Cyclovalone is a choleretic and cholagogic agent. J. Elks, C. Robin Ganellin. Dictionary of Drugs. p. ... A cholagogue is a medicinal agent which promotes the discharge of bile from the system, purging it downward. Deployment is no ... 1728). Cyclopaedia, or an Universal Dictionary of Arts and Sciences (first ed.), s.v. "Cholagogue". Websters Revised ...
It is used as a cholagogue and choleretic. Tauroursodeoxycholic acid, an epimer v t e. ...
Cholagogues and Choleretics. 54. 12. Diuretics. 53. 11. STAT3 Inhibitor. 53. 31. ...
Cholagogues and Choleretics / therapeutic use * Cholangiopancreatography, Endoscopic Retrograde* * Cholangitis, Sclerosing / ...
Cholagogues (0) see Cholagogues and Choleretics. Cholagogues and Choleretics (23) • Gastrointestinal agents that stimulate the ... Choleretics (0) see Cholagogues and Choleretics. Cholinergic Agents (178) • Any drug used for its actions on cholinergic ... flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). MeSH ...
0 (Anti-Inflammatory Agents); 0 (Cholagogues and Choleretics); 0 (Hypolipidemic Agents); 0 (MicroRNAs); 724L30Y2QR ( ...
Cholagogues and Choleretics / administration & dosage*. Cyclooxygenase Inhibitors / administration & dosage*. Dose-Response ... 0/Anticarcinogenic Agents; 0/Cholagogues and Choleretics; 0/Cyclooxygenase Inhibitors; 128-13-2/Ursodeoxycholic Acid; 38194-50- ...
Cholagogue; Choleretic; Clastogenic; Cocarcinogenic; Collagen-Sparing;. Cytoprotective; Cytotoxic TC50=200 ug/ml; DNA-Active; ... ug/ml; Aromatase-Inhibitor; CNS-Depressant; Cancer-Preventive; Choleretic. 5-20 mg/kg orl; Cytotoxic 50 ppm; ED50=3.75 ug/ml; ... Cancer-Preventive; Carcinogenic; Choleretic; Cyclooxygenase-Inhibitor IC50. (uM) =20; Diaphoretic?; Diuretic; HIV-RT-Inhibitor ...
Cholagogue WIC ; Choleretic 411 ; Clastogenic JBH ; CNS-Active WIC ; Co-carcinogenic PCF:44 ; Collagen-Sparing PM61:510 ; ... Choleretic DUKE1992B ; Cytotoxic JBH ; Diaphoretic? LRN-DEC90 ; Fungicide NIG ; Lipoxygenase-Inhibitor IC11=5 mM JAF38:688 ; ...
choleretic: An agent that promotes bile production.. cholesterol: A waxy, fat-like substance produced by the liver and found in ... cholagogue: A substance that causes the gallbladder to squeeze, increasing the discharge of bile. ...
It is a cholagogue and choleretic.. 16,16-dimethylprostaglandin E2. A synthetic prostaglandin E analog that protects the ...
Shop our wide range of premium essential oils and aromatherapy oils at fantastic prices. From a trusted ATC Member with discount for therapists!
It is used as a cholagogue and choleretic. Copyright © 2013. ...
It is used as a cholagogue and choleretic. Categories:. * Info Detergents. * Info Surface-Active Agents ...
P-Coumaric: antitumoral,antibacterial, antispasmodic,choleretic. - Chlorogenic: Antitumoral, antihipercholesterolimic, ... antioxidant, antiinflammatory, hepatoprotective, cholagogue, vulnerary. (Leaves). - Vitexin: antidermatitic, antiinflammatory, ...
It is a cholagogue and choleretic.
cholagogue. * choleretic. * cosmetic. * demulcent. * detoxicant. * diaphoretic. * digestive. * diuretic. * dye. * emetic. * ...
The root has choleretic, cholagogue, tonic, anti-rheumatic, bitter and alterative actions. Below […] ... The leaves are a rich source of vitamins, minerals and has diuretic, choleretic and anti-inflammatory actions. ...
The root has choleretic, cholagogue, tonic, anti-rheumatic, bitter and alterative actions. Below […] ... The leaves are a rich source of vitamins, minerals and has diuretic, choleretic and anti-inflammatory actions. ...
  • Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (dictionary.net)
  • A cholagogue is a medicinal agent which promotes the discharge of bile from the system, purging it downward. (wikipedia.org)
  • The artichoke is choleretic as stimulates the production of bile. (conua.com)
  • 3) to help increase bile flow (cholagogue and choleretic). (nutrichem.com)
  • A cholagogue is an agent that promotes the flow of bile into the intestine, especially as a result of contraction of the gallbladder. (smart-publications.com)
  • It is used as a cholagogue and choleretic (a bile purging agent). (hmdb.ca)
  • In traditional European medicine, the leaves of the artichoke (not the flower buds, which are the parts commonly cooked and eaten as a vegetable) were used as a diuretic to stimulate the kidneys and as a "choleretic" to stimulate the flow of bile from the liver and gallbladder. (westfloridahospital.com)
  • Bonus: Bitters also act as cholagogues and choleretics, "liver movers" that improve detoxification by encouraging the liver's production and excretion of bile. (tasteforlife.com)
  • Dandelion acts as a cholagogue , increasing flow of bile from the gallbladder into the duodenum. (commonsensehome.com)
  • It also acts as a choleretic, increasing bile production. (commonsensehome.com)
  • Dandelion herbal capsules are used in herbal medicine to help treat digestive disturbances (dyspepsia) and to help increase bile flow (cholagogue and choleretic). (lifestylemarkets.com)
  • The rationale for the use of the choleretic non-toxic bile acid ursodeoxycholic acid in CF-associated liver disease is to reduce the viscosity of bile and to replace toxic bile acids which accumulate in the hepatocyte. (elsevier.com)
  • A cholagogue is a substance (herb or other) that promotes the flow of bile from the gall bladder into the duodenum (the first part of the small intestine) and the liver. (chemainesmodelhealth.com)
  • A choleretic is a substance (herb or other) that stimulates the production of bile by the liver. (chemainesmodelhealth.com)
  • Cholagogue and choleretic herbs help regulate the flow of bile and are an important component of the Liver Regeneration Program. (drfostersessentials.com)
  • CHOLAGOGUE: Increases the flow of bile. (blogspot.com)
  • Measurements of bile acid excretion in bile, the biliary tree volume, and of the hormone choleretic effect in guinea pigs with proliferated bile ductules/ducts induced by α-naphthylisothiocyanate feeding indicated that glucagon, unlike secretin, stimulated canalicular bile flow. (elsevier.com)
  • Inhibition of prostaglandin synthesis by indomethacin administration (5 mg·kg -1 ·h -1 ) did not modify the choleretic effect of glucagon, and infusion of a glucagon analogue (TH-glucagon, 1.4 nmol·min -1 ·kg -1 ), which did not increase hepatic formation of adenosine 3'5'-cyclic monophosphate (cAMP), failed to stimulate bile flow. (elsevier.com)
  • Colchicine pretreatment (0.5 mg/kg ip) almost entirely prevented the choleretic effect of glucagon but did not modify spontaneous and bile acid-induced bile flow and the stimulatory effect of the hormone on glucose release and on hepatic formation of cAMP and inositol phosphates. (elsevier.com)
  • Constituents with eupeptic and mucose-protective activities, choleretic and cholagogues, antispasmodic and carminative, laxatives, anti-diarrheal and constituents with hypocholesterolemic effetcs. (unige.it)
  • The aqueous extract of the aerial parts of Lippia integrifolia has been assayed for its choleretic and antispasmodic effects. (bvsalud.org)
  • The leaves are a rich source of vitamins, minerals and has diuretic, choleretic and anti-inflammatory actions. (herbs.org)
  • The effects of the choleretic and digestant agent clanobutin sodium on liver and gallbladder functions were studied in beef cattle. (who.int)
  • Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic phase-II detoxification enzymes. (greenmedinfo.com)
  • It is the same for the biliary flow, the measurement of which shows a choleretic activity 2 times and half more important for the young shoot compared to the whole plant. (santi-shop.eu)
  • Bitter herbs are often hepatics & cholagogues (more on this in our biohacking Facebook group), and must be 'tasted' to produce these effects. (chemainesmodelhealth.com)
  • Cyclovalone is a choleretic and cholagogic agent. (wikipedia.org)
  • Sage helps in promoting digestion, giving acidity relive and has choleretic and cholagogue properties. (hubpages.com)
  • The efficacy of ultrasound-guided cholagogue-induced gallbladder emptying for differentiating obstructive from non-obstructive hepatobiliary diseases was studied in icteric dogs. (elsevier.com)
  • Thus, HD-03 can serve as a potent choleretic and anti-cholestatic agent. (bvsalud.org)
  • Hoda H. Ahmed , Some physiological and biochemical studies on the choleretic and cholagouge effects of clanobuin sodium in beef cattle, Alex. (who.int)
  • It is known to be both 'choleretic' (increasing bile production in the liver), and cholagogue (causing contraction of the gall bladder, releasing bile). (thelittlesupplementcompany.co.uk)
  • Used in Herbal Medicine as a liver protectant, to aid digestion, and to increase bile excretion by the liver (choleretic) and stimulate contraction of the gallbladder (cholagogue). (purefeast.com)